X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-11-12 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $16.85 | -100,000 | 12,967,049 | -1% | -$1,684,642 | ||||||
2024-11-12 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $16.85 | -100,000 | 11,665,600 | -1% | -$1,684,642 | ||||||
| M | 2024-11-11 | SPRY | Flynn James E | 10% | S - Sale | $18.01 | -563,270 | 10,514,657 | -5% | -$10,143,706 | |||||
| D | 2024-10-16 | SPRY | Scott Kathleen D. | CFO | S - Sale+OE | $16.00 | -12,500 | 13,199 | -49% | -$200,000 | |||||
2024-10-15 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $14.88 | -100,000 | 11,765,600 | -1% | -$1,487,595 | ||||||
2024-10-15 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $14.88 | -100,000 | 11,765,600 | -1% | -$1,487,595 | ||||||
2024-10-08 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $13.83 | -100,000 | 11,865,600 | -1% | -$1,382,775 | ||||||
2024-10-08 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $13.83 | -100,000 | 11,865,600 | -1% | -$1,382,775 | ||||||
| D | 2024-09-18 | SPRY | Karas Eric | Chief Commercial Officer | S - Sale+OE | $14.00 | -10,000 | 5,693 | -64% | -$140,000 | |||||
2024-09-17 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $12.93 | -100,000 | 11,965,600 | -1% | -$1,293,205 | ||||||
2024-09-17 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $12.93 | -100,000 | 11,965,600 | -1% | -$1,293,205 | ||||||
2024-09-10 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $11.50 | -100,000 | 12,065,600 | -1% | -$1,149,775 | ||||||
2024-09-10 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $11.50 | -100,000 | 12,065,600 | -1% | -$1,149,775 | ||||||
2024-08-26 | SPRY | Thompson Peter A. | Dir | S - Sale | $13.00 | -83,695 | 8,288,510 | -1% | -$1,088,035 | ||||||
2024-08-26 | SPRY | Orbimed Advisors LLC | Dir | S - Sale | $13.00 | -83,695 | 8,288,510 | -1% | -$1,088,035 | ||||||
| M | 2024-08-21 | SPRY | Thompson Peter A. | Dir | S - Sale | $13.24 | -868,682 | 8,372,205 | -9% | -$11,497,963 | |||||
| M | 2024-08-21 | SPRY | Orbimed Advisors LLC | Dir | S - Sale | $13.24 | -868,682 | 8,372,205 | -9% | -$11,497,963 | |||||
| D | 2024-08-20 | SPRY | Dorsey Brian | COO | S - Sale+OE | $15.00 | -50,000 | 6,024 | -89% | -$750,000 | |||||
| D | 2024-08-19 | SPRY | Karas Eric | Chief Commercial Officer | S - Sale+OE | $14.00 | -10,000 | 5,693 | -64% | -$140,000 | |||||
| D | 2024-08-20 | SPRY | Scott Kathleen D. | CFO | S - Sale+OE | $16.00 | -12,500 | 13,199 | -49% | -$200,000 | |||||
2024-08-20 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $15.03 | -100,000 | 12,165,600 | -1% | -$1,502,587 | ||||||
2024-08-20 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $15.03 | -100,000 | 12,165,600 | -1% | -$1,502,587 | ||||||
| D | 2024-08-13 | SPRY | Dorsey Brian | COO | S - Sale+OE | $13.00 | -30,000 | 6,024 | -83% | -$390,000 | |||||
2024-08-13 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $12.48 | -100,000 | 13,747,495 | -1% | -$1,247,555 | ||||||
2024-08-13 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $12.48 | -100,000 | 12,265,600 | -1% | -$1,247,555 | ||||||
2024-07-16 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $11.40 | -100,000 | 12,365,600 | -1% | -$1,140,295 | ||||||
2024-07-16 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $11.40 | -100,000 | 12,365,600 | -1% | -$1,140,295 | ||||||
2024-07-09 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.62 | -100,000 | 12,465,600 | -1% | -$961,725 | ||||||
2024-07-09 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.62 | -100,000 | 12,465,600 | -1% | -$961,725 | ||||||
| M | 2024-06-11 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.14 | -100,000 | 12,565,600 | -1% | -$913,917 | |||||
| M | 2024-06-11 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.14 | -100,000 | 12,565,600 | -1% | -$913,917 | |||||
| M | 2024-05-14 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.05 | -100,000 | 12,665,600 | -1% | -$905,441 | |||||
| M | 2024-05-14 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.05 | -100,000 | 14,307,793 | -1% | -$905,441 | |||||
2024-05-07 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.34 | -100,000 | 12,765,600 | -1% | -$934,365 | ||||||
2024-05-07 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.34 | -100,000 | 12,765,600 | -1% | -$934,365 | ||||||
2024-04-16 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.28 | -100,000 | 12,546,116 | -1% | -$928,005 | ||||||
2024-04-16 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.28 | -100,000 | 12,546,116 | -1% | -$928,005 | ||||||
2024-04-09 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.28 | -100,000 | 12,646,116 | -1% | -$927,735 | ||||||
2024-04-09 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.28 | -100,000 | 12,646,116 | -1% | -$927,735 | ||||||
| M | 2024-03-25 | SPRY | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $9.48 | +1,401,299 | 10,860,977 | +15% | +$13,289,410 | |||||
| M | 2024-03-22 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.12 | -97,610 | 12,746,116 | -1% | -$890,322 | |||||
| M | 2024-03-22 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.12 | -97,610 | 12,746,116 | -1% | -$890,322 | |||||
| M | 2024-03-19 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.03 | -2,390 | 12,843,726 | 0% | -$21,572 | |||||
| M | 2024-03-19 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.03 | -2,390 | 12,843,726 | 0% | -$21,572 | |||||
| M | 2024-03-13 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.14 | -100,000 | 12,846,116 | -1% | -$913,681 | |||||
| M | 2024-03-13 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.14 | -100,000 | 12,846,116 | -1% | -$913,681 | |||||
2024-02-29 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.02 | -3,782 | 12,946,116 | 0% | -$34,101 | ||||||
2024-02-29 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.02 | -3,782 | 12,946,116 | 0% | -$34,101 | ||||||
| M | 2024-02-26 | SPRY | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.02 | -99,478 | 12,949,898 | -1% | -$897,368 | |||||
| M | 2024-02-26 | SPRY | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.02 | -99,478 | 12,949,898 | -1% | -$897,368 | |||||
| M | 2023-09-28 | SPRY | Fitzpatrick Alexander A | GC | P - Purchase | $3.71 | +86,258 | 89,227 | >999% | +$319,954 | |||||
2023-09-21 | SPRY | Ra Capital Management, L.P. | Dir | P - Purchase | $3.03 | +2,700,000 | 9,459,678 | +40% | +$8,183,526 | ||||||
| D | 2023-09-01 | SPRY | Shawver Laura | Dir | S - Sale+OE | $7.71 | -100,000 | 210,346 | -32% | -$770,520 | |||||
2023-08-29 | SPRY | Ra Capital Management, L.P. | Dir | P - Purchase | $6.20 | +3,750,000 | 6,759,678 | +125% | +$23,250,000 | ||||||
2023-08-29 | SPRY | Orbimed Advisors LLC | Dir | P - Purchase | $6.20 | +500,000 | 9,240,887 | +6% | +$3,100,000 | ||||||
2023-08-29 | SPRY | Thompson Peter A. | Dir | P - Purchase | $6.20 | +500,000 | 9,240,887 | +6% | +$3,100,000 | ||||||
| DM | 2023-08-03 | SPRY | Shawver Laura | Dir | S - Sale+OE | $7.03 | -45,004 | 210,346 | -18% | -$316,489 | |||||
| DM | 2023-08-01 | SPRY | Shawver Laura | Dir | S - Sale+OE | $7.12 | -54,996 | 210,346 | -21% | -$391,841 | |||||
| D | 2023-07-07 | SPRY | Shawver Laura | Dir | S - Sale+OE | $6.36 | -8,858 | 210,346 | -4% | -$56,372 | |||||
| DM | 2023-07-03 | SPRY | Shawver Laura | Dir | S - Sale+OE | $6.48 | -91,142 | 210,346 | -30% | -$590,453 | |||||
| DM | 2023-06-01 | SPRY | Shawver Laura | Dir | S - Sale+OE | $6.84 | -100,000 | 210,346 | -32% | -$684,041 | |||||
| DM | 2022-11-09 | SPRY | Shawver Laura | Dir | S - Sale+OE | $5.42 | -143,896 | 210,346 | -41% | -$780,579 | |||||
2022-11-29 | SPRY | Scott Kathleen D. | CFO | P - Purchase | $6.24 | +8,250 | 8,250 | New | +$51,506 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |